Thursday, November 12, 2026

Brazilian Fintechs Deploy AI Credit Models to Add 7M Clients While Holding Risk Margins Stable

Nu Holdings and Inter & Co deployed AI-driven underwriting systems in 2025 that enabled rapid client growth without degrading credit performance. Nu's nuFormer model powered 100+ product launches while maintaining stable risk-adjusted margins. Inter added 7 million clients—its best year—with newer cohorts transacting faster than predecessors.

Brazilian Fintechs Deploy AI Credit Models to Add 7M Clients While Holding Risk Margins Stable
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Nu Holdings put its nuFormer AI model into production in 2025 and launched over 100 products and features across its Latin American markets while keeping risk-adjusted net interest margins stable quarter-over-quarter. The deployment demonstrates how machine learning models can accelerate product velocity without sacrificing underwriting quality.

Inter & Co welcomed 7 million new clients in 2025, marking its strongest annual performance. The fintech maintains industry-leading funding costs at 65.6% of Brazil's CDI benchmark rate. Newer client cohorts are transacting faster and more frequently than older ones, indicating improved targeting from automated credit decisioning.

The AI models handle real-time portfolio monitoring alongside automated underwriting. Traditional banks process credit applications in days using manual review processes. AI systems evaluate hundreds of data points in seconds, including transaction patterns, payment histories, and behavioral signals invisible to rule-based systems.

Brazilian fintechs face unique credit risk challenges. The country's CDI rate fluctuates significantly, compressing margins during rate spikes. AI models adjust credit lines and pricing dynamically as portfolio conditions shift, maintaining profitability across rate cycles.

Nu's stable risk-adjusted margins despite rapid expansion suggest the nuFormer model identifies creditworthy clients more accurately than previous methods. The company avoided the common tradeoff between growth speed and credit quality that plagued earlier fintech lending waves.

Inter's accelerating cohort performance reveals another AI advantage. Newer clients transact more because better targeting matches products to customer needs upfront. Manual underwriting relies on demographic proxies; machine learning identifies behavioral patterns that predict product usage.

The 2025 results contrast with 2021-2022, when Brazilian fintechs expanded rapidly but suffered rising non-performing loans. AI models trained on post-pandemic data captured changing payment behaviors that rule-based systems missed.

Client acquisition costs declined as AI improved approval rates for qualified applicants while rejecting riskier profiles. Fewer false negatives mean less marketing waste; fewer false positives reduce collection expenses.

Both companies now iterate credit models continuously. Nu launched 100+ features by testing algorithms on live portfolios and rolling out improvements monthly rather than in annual cycles. This cadence was impossible under manual underwriting governance.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com